These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 8680005

  • 1. [Effects of potentiation and rapid action in models of venous thrombosis in dogs upon combined administration of the plasminogen tissue activator and urokinase modified by fibrinogen].
    Maksimenko AV, Tishchenko EG, Petrova ML, Golubykh VL.
    Biull Eksp Biol Med; 1996 Jan; 121(1):48-51. PubMed ID: 8680005
    [No Abstract] [Full Text] [Related]

  • 2. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
    Collen D.
    Prog Hemost Thromb; 1986 Jan; 8():1-18. PubMed ID: 3104986
    [No Abstract] [Full Text] [Related]

  • 3. [Combined thrombolysis by pharmacokinetically different plasminogen activators].
    Maksimenko AV.
    Bioorg Khim; 1998 May; 24(5):376-80. PubMed ID: 9661792
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Use of urokinase in pregnancy. Two success stories.
    La Valleur J, Molina E, Williams PP, Rolnick SJ.
    Postgrad Med; 1996 May; 99(5):269-70, 272-3. PubMed ID: 8650092
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Venous thrombolysis by tissue-type plasminogen activator in conjunction with the urokinase-fibrinogen covalent conjugate. Effects of potentiation and faster action in dogs.
    Maksimenko AV, Tischenko EG, Petrov AD, Petrova ML, Golubykh VL.
    Appl Biochem Biotechnol; 1996 May; 61(1-2):123-8. PubMed ID: 9100350
    [Abstract] [Full Text] [Related]

  • 15. [Coronary thrombolysis by t-PA and pro-UK].
    Kanmatsuse K, Suzuki T, Kajiwara N.
    Nihon Rinsho; 1989 Apr; 47(4):910-6. PubMed ID: 2501541
    [No Abstract] [Full Text] [Related]

  • 16. Fibrinolysis with intrathrombic injection of urokinase and tissue-type plasminogen activator. Results in a new model of subacute venous thrombosis.
    Valji K, Bookstein JJ.
    Invest Radiol; 1987 Jan; 22(1):23-7. PubMed ID: 3102398
    [Abstract] [Full Text] [Related]

  • 17. Endotoxin-induced intravascular coagulation in rabbits: effect of tissue plasminogen activator vs urokinase of PAI generation, fibrin deposits and mortality.
    Paloma MJ, Páramo JA, Rocha E.
    Thromb Haemost; 1995 Dec; 74(6):1578-82. PubMed ID: 8772240
    [Abstract] [Full Text] [Related]

  • 18. Experiences with pro-urokinase and potentiation of its fibrinolytic effect by urokinase and by tissue plasminogen activator.
    Gurewich V.
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):16B-21B. PubMed ID: 3117859
    [Abstract] [Full Text] [Related]

  • 19. [Fibrinolytic therapy of acute venous thrombosis].
    Theiss W.
    Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir; 1990 Nov; ():443-8. PubMed ID: 1983587
    [Abstract] [Full Text] [Related]

  • 20. Potentiation by heparin fragment CY 222 (Choay) of thrombolysis induced by human tissue-type plasminogen activator.
    Juhan-Vague I, Stassen JM, Alessi MC, Elias A, Aillaud MF, Serradimigni A, Collen D.
    Semin Thromb Hemost; 1989 Oct; 15(4):390-4. PubMed ID: 2554499
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.